Cargando…

Transportan 10 improves the anticancer activity of cisplatin

The aim of this paper was to examine whether cell-penetrating peptides (CPPs) such as transportan 10 (TP10) or protein transduction domain (PTD4) may improve the anticancer activity of cisplatin (cPt). The complexes of TP10 or PTD4 with cPt were used in the experiments. They were carried out on two...

Descripción completa

Detalles Bibliográficos
Autores principales: Izabela, Rusiecka, Jarosław, Ruczyński, Magdalena, Alenowicz, Piotr, Rekowski, Ivan, Kocić
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823340/
https://www.ncbi.nlm.nih.gov/pubmed/26899863
http://dx.doi.org/10.1007/s00210-016-1219-5
_version_ 1782425895450968064
author Izabela, Rusiecka
Jarosław, Ruczyński
Magdalena, Alenowicz
Piotr, Rekowski
Ivan, Kocić
author_facet Izabela, Rusiecka
Jarosław, Ruczyński
Magdalena, Alenowicz
Piotr, Rekowski
Ivan, Kocić
author_sort Izabela, Rusiecka
collection PubMed
description The aim of this paper was to examine whether cell-penetrating peptides (CPPs) such as transportan 10 (TP10) or protein transduction domain (PTD4) may improve the anticancer activity of cisplatin (cPt). The complexes of TP10 or PTD4 with cPt were used in the experiments. They were carried out on two non-cancer (HEK293 (human embryonic kidney) and HEL299 (human embryo lung)) and two cancer (HeLa (human cervical cancer) and OS143B (human osteosarcoma 143B)) cell lines. Both complexes were tested (MTT assay) with respect to their anticancer or cytotoxic actions. TAMRA (fluorescent dye)-stained preparations were visualized in a fluorescence microscope. The long-term effect of TP10 + cPt and its components on non-cancer and cancer cell lines was observed in inverted phase contrast microscopy. In the MTT test (cell viability assay), the complex of TP10 + cPt produced a more potent effect on the cancer cell lines (HeLa, OS143B) in comparison to that observed after separate treatment with TP10 or cPt. At the same time, the action of the complex and its components was rather small on non-cancer cell lines. On the other hand, a complex of another CPP with cPt, i.e., PTD4 + cPt, was without a significant effect on the cancer cell line (OS143B). The images of the fluorescent microscopy showed TAMRA-TP10 or TAMRA-TP10 + cPt in the interior of the HeLa cells. In the case of TAMRA-PTD4 or TAMRA-PTD4 + cPt, only the first compound was found inside the cancer cell line. In contrast, none of the tested compounds gained access to the interior of the non-cancer cells (HEK293, HEL299). Long-term incubation with the TP10 + cPt (estimated by inverted phase contrast microscopy) lead to an enhanced action of the complex on cell viability (decrease in the number of cells and change in their morphology) as compared with that produced by each single agent. With regard to the tested CPPs, only TP10 improved the anticancer activity of cisplatin if both compounds were used in the form of a complex. Additionally, the complex was relatively safe for non-cancer cells. What is more, TP10 also produced an anticancer effect on HeLa and OS143B cell lines.
format Online
Article
Text
id pubmed-4823340
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-48233402016-04-20 Transportan 10 improves the anticancer activity of cisplatin Izabela, Rusiecka Jarosław, Ruczyński Magdalena, Alenowicz Piotr, Rekowski Ivan, Kocić Naunyn Schmiedebergs Arch Pharmacol Original Article The aim of this paper was to examine whether cell-penetrating peptides (CPPs) such as transportan 10 (TP10) or protein transduction domain (PTD4) may improve the anticancer activity of cisplatin (cPt). The complexes of TP10 or PTD4 with cPt were used in the experiments. They were carried out on two non-cancer (HEK293 (human embryonic kidney) and HEL299 (human embryo lung)) and two cancer (HeLa (human cervical cancer) and OS143B (human osteosarcoma 143B)) cell lines. Both complexes were tested (MTT assay) with respect to their anticancer or cytotoxic actions. TAMRA (fluorescent dye)-stained preparations were visualized in a fluorescence microscope. The long-term effect of TP10 + cPt and its components on non-cancer and cancer cell lines was observed in inverted phase contrast microscopy. In the MTT test (cell viability assay), the complex of TP10 + cPt produced a more potent effect on the cancer cell lines (HeLa, OS143B) in comparison to that observed after separate treatment with TP10 or cPt. At the same time, the action of the complex and its components was rather small on non-cancer cell lines. On the other hand, a complex of another CPP with cPt, i.e., PTD4 + cPt, was without a significant effect on the cancer cell line (OS143B). The images of the fluorescent microscopy showed TAMRA-TP10 or TAMRA-TP10 + cPt in the interior of the HeLa cells. In the case of TAMRA-PTD4 or TAMRA-PTD4 + cPt, only the first compound was found inside the cancer cell line. In contrast, none of the tested compounds gained access to the interior of the non-cancer cells (HEK293, HEL299). Long-term incubation with the TP10 + cPt (estimated by inverted phase contrast microscopy) lead to an enhanced action of the complex on cell viability (decrease in the number of cells and change in their morphology) as compared with that produced by each single agent. With regard to the tested CPPs, only TP10 improved the anticancer activity of cisplatin if both compounds were used in the form of a complex. Additionally, the complex was relatively safe for non-cancer cells. What is more, TP10 also produced an anticancer effect on HeLa and OS143B cell lines. Springer Berlin Heidelberg 2016-02-22 2016 /pmc/articles/PMC4823340/ /pubmed/26899863 http://dx.doi.org/10.1007/s00210-016-1219-5 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Izabela, Rusiecka
Jarosław, Ruczyński
Magdalena, Alenowicz
Piotr, Rekowski
Ivan, Kocić
Transportan 10 improves the anticancer activity of cisplatin
title Transportan 10 improves the anticancer activity of cisplatin
title_full Transportan 10 improves the anticancer activity of cisplatin
title_fullStr Transportan 10 improves the anticancer activity of cisplatin
title_full_unstemmed Transportan 10 improves the anticancer activity of cisplatin
title_short Transportan 10 improves the anticancer activity of cisplatin
title_sort transportan 10 improves the anticancer activity of cisplatin
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823340/
https://www.ncbi.nlm.nih.gov/pubmed/26899863
http://dx.doi.org/10.1007/s00210-016-1219-5
work_keys_str_mv AT izabelarusiecka transportan10improvestheanticanceractivityofcisplatin
AT jarosławruczynski transportan10improvestheanticanceractivityofcisplatin
AT magdalenaalenowicz transportan10improvestheanticanceractivityofcisplatin
AT piotrrekowski transportan10improvestheanticanceractivityofcisplatin
AT ivankocic transportan10improvestheanticanceractivityofcisplatin